Omicron subvariants resistant to key antibody treatments are increasing every week in the U.S.

The subvariants BQ.1 and BQ.1.1 now represent 27% of infections in the U.S., a significant jump from the week prior when they made up about 16% of new cases.

Omicron subvariants resistant to key antibody treatments are increasing every week in the U.S.
The subvariants BQ.1 and BQ.1.1 now represent 27% of infections in the U.S., a significant jump from the week prior when they made up about 16% of new cases.